- Oxford Endovascular, a British MedTech company, raised $10m in a series A funding round
- Backers included a £3m investment from new investors Vulpes Investment Management, who joined to lead the round and funds from the Additio Investment Group
- Existing investors Oxford Sciences Innovation PLC, Parkwalk Advisors, Perivoli Innovations, Oxford Investment Consultants, the University of Oxford and private individuals also followed on
- The raise will enable the company to complete development work and gain first in-human data through an early feasibility clinical study
- This will then followed by a further fundraise for larger FDA and CE Mark clinical trials to enter various international markets valued at over $1billion
- Led by Mike Karim, CEO, Oxford Endovascular is developing a treatment for brain aneurysms
